Immunotherapy. 2011;3(11):1303-1306. As discussed above, the proof-of-principle studies using both anti-CD3 antibodies (teplizumab and otelixizumab) showed effects on surrogate markers (C-peptide ...
AST-008: A novel approach to TLR9 agonism with PD-1 blockade for anti-PD-1 refractory Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (CSCC). This is an ASCO Meeting Abstract from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results